Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 49,167 shares of the company’s stock, valued at approximately $119,000. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.16% of Rexahn Pharmaceuticals at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. Renaissance Technologies LLC lifted its holdings in shares of Rexahn Pharmaceuticals by 17.6% in the first quarter. Renaissance Technologies LLC now owns 5,758,391 shares of the company’s stock worth $2,937,000 after buying an additional 862,000 shares in the last quarter. Susquehanna International Group LLP purchased a new position in shares of Rexahn Pharmaceuticals in the second quarter worth $2,905,000. Finally, Sabby Management LLC purchased a new position in shares of Rexahn Pharmaceuticals in the second quarter worth $706,000.
Rexahn Pharmaceuticals, Inc. (RNN) traded down $0.03 during trading on Thursday, reaching $2.05. 160,800 shares of the company were exchanged, compared to its average volume of 445,575. Rexahn Pharmaceuticals, Inc. has a 52 week low of $1.30 and a 52 week high of $7.10.
Several equities analysts have recently commented on RNN shares. HC Wainwright set a $20.00 target price on shares of Rexahn Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, September 11th. ValuEngine raised shares of Rexahn Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 2nd. Seaport Global Securities reaffirmed a “buy” rating and set a $13.00 price target on shares of Rexahn Pharmaceuticals in a research note on Friday, October 6th. Finally, Zacks Investment Research raised shares of Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research note on Wednesday, October 4th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $13.65.
Rexahn Pharmaceuticals Profile
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.